{"id":"W2052266277","doi":"10.1016/j.ygyno.2009.01.012","title":"A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer","year":2009,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"ca_institutions":"Women's Health Research Institute","funders":"AstraZeneca","keywords":"Fulvestrant; Medicine; Ovarian cancer; Clinical endpoint; Internal medicine; Response Evaluation Criteria in Solid Tumors; Cancer; Oncology; Progressive disease; Phases of clinical research; Gastroenterology; Breast cancer; Toxicity; Disease; Estrogen receptor; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001434913,0.001191627,0.002337786,0.0005338374,0.0004472451,0.0008523798,0.0008542825,0.001286019,0.002737711],"category_scores_gemma":[0.001161301,0.0004614952,0.00135763,0.0004169193,0.001195677,0.0008189505,0.0003776954,0.002766516,0.0004933688],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006516234,"about_ca_system_score_gemma":0.001121844,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001388913,"about_ca_topic_score_gemma":0.002423345,"domain_scores_codex":[0.9996364,0.0001793905,0.00001773322,0.00004684093,0.00002735943,0.00009218913],"domain_scores_gemma":[0.9991738,0.0002016791,0.0001223256,0.00009766442,0.00003363996,0.0003709404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7847077,0.04925874,0.006422698,0.0006722732,0.001361161,0.0004426093,0.0004012529,0.002858566,0.0385753,0.0004328584,0.002130827,0.1127359],"study_design_scores_gemma":[0.5057384,0.4780792,0.008333879,0.00002321216,0.0004030903,0.0004424494,0.00009228735,0.0009394637,0.003928147,0.0002048306,0.001784879,0.00003009993],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961565,0.001524902,0.0002829915,0.0002708427,0.00009811184,0.0006725303,0.0002906154,0.00004290842,0.0006606221],"genre_scores_gemma":[0.9943124,0.001536294,0.0007078501,0.0003662284,0.0001616556,0.0006468589,0.0008622208,0.00001958828,0.001386921],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002737711,"threshold_uncertainty_score":0.009158552,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05204197889891651,"score_gpt":0.3916236740312822,"score_spread":0.3395816951323657,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}